Sanofi S.A., FR0000120578

Sanofi stock falls 1.16 percent as pipeline deal draws scrutiny

Published on 10/05/2026 at 22:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sanofi stock traded at EUR 69.99 on October 5, 2026, after a USD 1 billion upfront payment expanded its Regeneron alliance. Six analysts set an EUR 90.50 average target.

Isometric 3D render of a translucent violet-blue cube containing a glowing molecular structure, a vaccine vial, a tablet blister pack, and a laboratory microscope — Sanofi FR0000120578 isometric 3D violet cube enclosing molecular structure, vaccine vial, blister pack, and microscope, Illustration mit AI erstellt.

Sanofi stock (ISIN FR0000120578) was last at EUR 69.99 on Euronext Paris on October 5, 2026 at 5:36 p.m. CEST, down 1.16 percent on the session. The company is expanding its Regeneron partnership with four new antibody programs, a move that puts pipeline rebuilding at the center of the investment case.

A USD 8 billion alliance reset

According to Sanofi on October 1, 2026, the expanded agreement covers four long-acting antibodies targeting IL-13, IL-4xIL-13, IL-4 and IL-4R alpha. One asset, REGN20423, is already in a Phase 1 study for atopic dermatitis, while the other three are expected to enter clinical studies in 2027.

The financial structure splits development and commercialization costs equally and divides future profits 50:50. The Business Standard reported on October 2, 2026, that Sanofi will pay USD 1 billion upfront, with up to USD 7 billion in additional milestone payments.

Cash cost meets pipeline need

The deal gives Sanofi commercial responsibility while Regeneron leads research and development. That division limits Sanofi's direct development burden, but the upfront payment is immediate while the milestone payments depend on clinical, regulatory and commercial progress.

The strategic benefit is tied to the long-term immunology franchise. The four programs target type 2 inflammation pathways associated with Dupixent, yet early-stage development leaves a substantial gap between the USD 8 billion potential value and any eventual product revenue.

Consensus target remains above price

finanzen.ch reported on September 30, 2026, that six analysts covered Sanofi during the preceding month, with four Buy ratings and two Hold ratings. The average target was EUR 90.50, the published targets ran from EUR 80 to EUR 95, and the average target lies 29.3 percent above the EUR 69.99 reference price.

The consensus therefore reflects a gap between current market pricing and the analysts' valuation framework. The stock's immediate test is different: at EUR 69.99, it stood EUR 0.24 above the current 52-week low of EUR 69.75, while the 52-week high was EUR 91.15.

Third quarter results arrive October 30

Sanofi's next scheduled reporting event is October 30, 2026, when management will review third quarter results in a live audio webcast. The date is listed on Sanofi's investor page.